Skip to Main Content

A former AstraZeneca communications executive was accused of insider trading in connection with a partnership with Daiichi Sankyo to develop and market a cancer drug, according to a lawsuit filed by the U.S. Securities and Exchange Commission.

Hugues Pierre Joublin, 54, was employed as the global head of corporate affairs for oncology when he learned in early March 2019 that AstraZeneca was holding confidential talks with Daiichi Sankyo about a global development and commercialization agreement. Within a week, he purchased 500 American Depository Shares of Daiichi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment